See more : Greenyard NV (0JZ8.L) Income Statement Analysis – Financial Results
Complete financial analysis of Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fujian Cosunter Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Ihara Science Corporation (5999.T) Income Statement Analysis – Financial Results
- Huabao International Holdings Limited (HUABF) Income Statement Analysis – Financial Results
- Shih-Kuen Plastics Co., Ltd. (4305.TWO) Income Statement Analysis – Financial Results
- Paradise Co., Ltd. (034230.KQ) Income Statement Analysis – Financial Results
- Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRES.BA) Income Statement Analysis – Financial Results
Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cosunter.com
About Fujian Cosunter Pharmaceutical Co., Ltd.
Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It offers Chinese patent medicines in the areas of liver diseases, andrology, cardiovascular, and other fields. The company was founded in 2001 and is based in Fuzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 422.71M | 385.77M | 370.44M | 368.49M | 414.87M | 402.40M | 296.12M | 312.88M | 308.92M | 254.47M | 178.15M | 125.79M | 105.04M |
| Cost of Revenue | 186.54M | 158.77M | 138.35M | 124.68M | 93.40M | 65.97M | 38.58M | 40.82M | 37.63M | 36.39M | 26.03M | 17.85M | 15.24M |
| Gross Profit | 236.18M | 227.00M | 232.10M | 243.81M | 321.47M | 336.43M | 257.54M | 272.07M | 271.29M | 218.07M | 152.13M | 107.94M | 89.80M |
| Gross Profit Ratio | 55.87% | 58.84% | 62.65% | 66.16% | 77.49% | 83.61% | 86.97% | 86.95% | 87.82% | 85.70% | 85.39% | 85.81% | 85.49% |
| Research & Development | 132.96M | 185.46M | 68.99M | 47.47M | 53.21M | 69.65M | 58.87M | 60.81M | 22.49M | 15.07M | 10.69M | 6.35M | 0.00 |
| General & Administrative | 114.92M | 17.55M | 15.09M | 12.31M | 12.88M | 17.44M | 14.94M | 12.71M | 10.22M | 6.46M | 6.02M | 6.62M | 21.66M |
| Selling & Marketing | 189.70M | 177.21M | 169.79M | 144.71M | 211.35M | 209.96M | 139.16M | 110.87M | 107.95M | 79.27M | 54.39M | 34.61M | 27.45M |
| SG&A | 306.48M | 194.77M | 184.88M | 157.02M | 224.23M | 227.40M | 154.10M | 123.58M | 118.17M | 85.73M | 60.41M | 41.23M | 49.11M |
| Other Expenses | 92.23M | -3.13M | -1.21M | 188.16K | -397.38K | -290.94K | -1.81M | 4.69M | 7.27M | 3.14M | 1.19M | 3.07M | 1.46M |
| Operating Expenses | 531.67M | 447.53M | 295.13M | 230.89M | 307.45M | 321.75M | 229.05M | 208.00M | 161.85M | 123.78M | 87.62M | 60.26M | 50.64M |
| Cost & Expenses | 718.21M | 606.30M | 433.47M | 355.56M | 400.85M | 387.72M | 267.63M | 248.82M | 199.49M | 160.17M | 113.65M | 78.11M | 65.88M |
| Interest Income | 4.27M | 5.56M | 4.03M | 1.27M | 1.77M | 5.84M | 12.02M | 10.40M | 6.04M | 966.14K | 1.11M | 393.95K | -0.88 |
| Interest Expense | 35.03M | 10.59M | 9.13M | 8.94M | 7.49M | 1.15M | 11.96M | 10.35M | 23.64K | 14.60K | 52.25K | 40.90K | 391.08K |
| Depreciation & Amortization | 72.14M | 61.69M | 53.00M | 38.05M | 35.46M | 23.86M | 15.50M | 12.33M | 8.55M | 6.93M | 5.87M | 4.72M | 662.10K |
| EBITDA | -190.86M | -94.23M | 15.41M | 49.99M | 53.98M | 40.90M | 43.71M | 75.78M | 130.52M | 105.47M | 70.38M | 52.39M | 39.35M |
| EBITDA Ratio | -45.15% | -23.10% | 4.95% | 17.39% | 13.26% | 9.61% | 15.01% | 24.56% | 42.47% | 41.72% | 39.80% | 42.20% | 37.46% |
| Operating Income | -295.49M | -160.29M | -44.48M | 15.16M | 12.55M | 12.05M | 36.96M | 69.82M | 114.14M | 94.52M | 65.12M | 47.60M | 38.69M |
| Operating Income Ratio | -69.90% | -41.55% | -12.01% | 4.11% | 3.02% | 2.99% | 12.48% | 22.32% | 36.95% | 37.14% | 36.55% | 37.84% | 36.83% |
| Total Other Income/Expenses | -2.54M | -3.13M | -1.21M | 188.16K | -397.38K | -290.94K | -1.81M | 4.67M | 7.26M | 4.00M | 2.17M | 3.17M | 1.45M |
| Income Before Tax | -298.03M | -163.42M | -45.69M | 15.35M | 12.15M | 11.76M | 35.16M | 74.49M | 121.40M | 98.52M | 67.29M | 50.77M | 40.13M |
| Income Before Tax Ratio | -70.50% | -42.36% | -12.33% | 4.17% | 2.93% | 2.92% | 11.87% | 23.81% | 39.30% | 38.72% | 37.77% | 40.36% | 38.21% |
| Income Tax Expense | 76.87M | -22.86M | -11.53M | -1.18M | -435.41K | -4.98M | 1.59M | 8.08M | 17.91M | 14.75M | 10.02M | 7.61M | 6.31M |
| Net Income | -348.59M | -127.40M | -34.89M | 14.82M | 10.74M | 16.48M | 33.57M | 66.41M | 103.49M | 83.77M | 57.26M | 43.16M | 33.82M |
| Net Income Ratio | -82.46% | -33.03% | -9.42% | 4.02% | 2.59% | 4.10% | 11.33% | 21.23% | 33.50% | 32.92% | 32.14% | 34.31% | 32.20% |
| EPS | -2.19 | -0.80 | -0.23 | 0.11 | 0.08 | 0.12 | 0.24 | 0.47 | 0.92 | 1.50 | 0.51 | 0.39 | 0.31 |
| EPS Diluted | -2.19 | -0.80 | -0.23 | 0.11 | 0.08 | 0.12 | 0.24 | 0.47 | 0.92 | 1.50 | 0.51 | 0.39 | 0.31 |
| Weighted Avg Shares Out | 159.27M | 159.18M | 149.41M | 140.00M | 140.00M | 137.37M | 139.86M | 140.00M | 111.99M | 56.00M | 112.28M | 112.10M | 107.38M |
| Weighted Avg Shares Out (Dil) | 159.27M | 159.18M | 149.41M | 140.38M | 140.00M | 137.37M | 139.86M | 141.30M | 111.99M | 56.00M | 112.28M | 112.10M | 107.38M |
Source: https://incomestatements.info
Category: Stock Reports